Last reviewed · How we verify
Feiba VH
At a glance
| Generic name | Feiba VH |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery (PHASE2)
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
- FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) (PHASE3)
- FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients (PHASE2)
- A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab (PHASE4)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Feiba VH CI brief — competitive landscape report
- Feiba VH updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI